FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293230091> ?p ?o ?g. }

• W4293230091 abstract "<h3>Background and importance</h3> In the context of the COVID-19 pandemic, one of the strategies implemented to minimise patient visits to health centres was switching the administration of tocilizumab (TCZ) from intravenous (IV) to subcutaneous (SC). <h3>Aim and objectives</h3> To evaluate the effectiveness and safety of switching from IV to SC TCZ. <h3>Material and methods</h3> Retrospective observational study conducted in a tertiary hospital including patients receiving active treatment of IV TCZ during the period March–April 2020. Data were collected on the following variables: age, sex, pathology, switching to SC TCZ, switching back to IV administration, physician assessment or patient self-assessment, as well as adverse reactions. The follow-up period was 1 year. <h3>Results</h3> A total of 45 patients were included, with a median age of 54 (40–62) years. Women represented 85%. Patients included were diagnosed with rheumatoid arthritis (49%), juvenile idiopathic arthritis (18%), Graves disease (13%), lupus (2%), spondylarthritis (2%) and other diagnoses (16%). The prescribing physicians were rheumatologists (62%), internists (24%) and paediatricians (13%). Of 45 patients, 71% (n=32) switched to SC TCZ during the study period. 86% of rheumatology, 83% of paediatrics and 27% of internal medicine patients changed to SC TCZ. Aggravation after switching to SC TCZ was reported in 7/32 (22%) cases (5 with rheumatoid arthritis and 2 with juvenile idiopathic arthritis). All of these switched back to IV administration, plus 4 additional patients for undetermined reasons. Of those who switched back to IV administration due to clinical worsening, 4 reported improvement afterwards. Regarding safety, only 2 patients suffered adverse reactions after switching to SC (injection site reaction, palpitations, tremor and oedema). Neither of them switched back to IV administration. <h3>Conclusion and relevance</h3> One-fifth of the patients reported loss of effectiveness when changing from IV to SC form, and one-third switched back to IV administration. Regarding safety, the toxicity profile of both forms was similar to other studies. The effectiveness results observed are in contrast with the MUSASHI study, which did not report loss of efficacy after switching from IV to SC. However, effectiveness was not measured using the internationally validated ordinary objective scales (DAS28, CDAI), but physician subjective assessments or patient self-assessments, which represents a significative limitation for our study. <h3>References and/or acknowledgements</h3> https://doi.org/10.3899/jrheum.140665 <h3>Conflict of interest</h3> No conflict of interest" @default.
• W4293230091 created "2022-08-27" @default.
• W4293230091 creator A5031649201 @default.
• W4293230091 creator A5032209327 @default.
• W4293230091 creator A5038472808 @default.
• W4293230091 creator A5050203458 @default.
• W4293230091 creator A5057212295 @default.
• W4293230091 date "2022-03-01" @default.
• W4293230091 modified "2023-09-27" @default.
• W4293230091 title "4CPS-263 Evaluation of the effectiveness and safety of switching from intravenous to subcutaneous tocilizumab" @default.
• W4293230091 doi "https://doi.org/10.1136/ejhpharm-2022-eahp.240" @default.
• W4293230091 hasPublicationYear "2022" @default.
• W4293230091 type Work @default.
• W4293230091 citedByCount "0" @default.
• W4293230091 crossrefType "proceedings-article" @default.
• W4293230091 hasAuthorship W4293230091A5031649201 @default.
• W4293230091 hasAuthorship W4293230091A5032209327 @default.
• W4293230091 hasAuthorship W4293230091A5038472808 @default.
• W4293230091 hasAuthorship W4293230091A5050203458 @default.
• W4293230091 hasAuthorship W4293230091A5057212295 @default.
• W4293230091 hasBestOaLocation W42932300911 @default.
• W4293230091 hasConcept C126322002 @default.
• W4293230091 hasConcept C2776390293 @default.
• W4293230091 hasConcept C2777178219 @default.
• W4293230091 hasConcept C2779134260 @default.
• W4293230091 hasConcept C42219234 @default.
• W4293230091 hasConcept C71924100 @default.
• W4293230091 hasConceptScore W4293230091C126322002 @default.
• W4293230091 hasConceptScore W4293230091C2776390293 @default.
• W4293230091 hasConceptScore W4293230091C2777178219 @default.
• W4293230091 hasConceptScore W4293230091C2779134260 @default.
• W4293230091 hasConceptScore W4293230091C42219234 @default.
• W4293230091 hasConceptScore W4293230091C71924100 @default.
• W4293230091 hasLocation W42932300911 @default.
• W4293230091 hasOpenAccess W4293230091 @default.
• W4293230091 hasPrimaryLocation W42932300911 @default.
• W4293230091 hasRelatedWork W1987294331 @default.
• W4293230091 hasRelatedWork W2012279943 @default.
• W4293230091 hasRelatedWork W2035343580 @default.
• W4293230091 hasRelatedWork W2134133792 @default.
• W4293230091 hasRelatedWork W2232273633 @default.
• W4293230091 hasRelatedWork W2558297493 @default.
• W4293230091 hasRelatedWork W2736593664 @default.
• W4293230091 hasRelatedWork W2996380604 @default.
• W4293230091 hasRelatedWork W3087945819 @default.
• W4293230091 hasRelatedWork W4239841759 @default.
• W4293230091 isParatext "false" @default.
• W4293230091 isRetracted "false" @default.
• W4293230091 workType "article" @default.